Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are aged 2 years or older but under 35 years old at the time of joining the trial
- People who have been newly diagnosed with classical Hodgkin lymphoma, confirmed by examination of tissue samples reviewed by at least 2 specialist pathology centres
- People whose major organs (such as heart, liver, and kidneys) are functioning at an adequate level
- People, or their parents or legal guardians, who are willing to sign a written consent form to participate
Who may not be able to join:
- People diagnosed with a specific subtype called nodular lymphocyte-predominant Hodgkin lymphoma
- People who had a weakened immune system before their diagnosis, including those with inherited immune disorders, organ transplant recipients, children currently taking immune-suppressing medications, or people known to be HIV-positive
- People who are currently pregnant, or who are breastfeeding and plan to continue doing so
- People who have received steroid medications (taken by mouth or injection throughout the body) within the 28 days before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: YI JIN GAO, MD, Shanghai Children's Medical Center
Phone: 86-21-38087513
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Early complete metabolic response rate for the entire group; Late complete metabolic response rate in intermediate/high risk group; Complete metabolic response rate in intermediate/high risk group after modified Check Mate 744 regimens; Overall survival rate for the entire group and each risk group
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.